Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  thalidomide
Find trials that include:  Any drugs shown
Results 1-6 of 6 for your search:
Start Over
Study of Dexamethasone Plus IXAZOMIB or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: C16011, NCI-2012-02752, 2011-005468-10, C16011-CTIL, NL41603.028.12, U1111-1164-7621, NCT01659658
Thalidomide and Dexamethasone after High-Dose Melphalan and Peripheral Blood Stem Cell Transplant in Treating Patients with Multiple Myeloma
Phase: Phase II
Type: Treatment
Age: 18 to 75
Trial IDs: MT2003-13, NCI-2010-01413, 0312M54569, 2004LS001, NCT00293306, UMN-2004LS001, UMN-MT2003-13, UMN-0312M54569, NCT00177047
Autologous Stem Cell Transplant Followed by Maintenance Therapy in Treating Elderly Patients with Multiple Myeloma
Phase: Phase II
Type: Treatment
Age: 65 to 85
Trial IDs: 201208775, NCI-2013-00883, 10120146, NCT01849783
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CR103015, NCI-2014-02217, 2013-003491-12, 54767414MMY1001, NCT01998971
Cyclophosphamide or Thalidomide after Stem Cell Transplant in Treating Younger Patients with Solid Tumors
Phase: No phase specified
Type: Treatment
Age: 5 to 21
Trial IDs: 201209088, NCI-2012-01541, NCT01661400
Thalidomide to Overcome Lenalidomide Resistance after Autologous Hematopoietic Stem Cell Transplant in Treating Patients with Multiple Myeloma
Phase: No phase specified
Type: Natural history/Epidemiology, Treatment
Age: 18 and over
Trial IDs: 2011-0806, NCI-2014-00920, NCI-2014-00157, NCT01927718
Start Over